American Society of Hematology

Friday Scientific Workshops

The following information is preliminary and subject to change.

The Friday Scientific Workshops are interactive discussions of the latest scientific developments in a particular field of hematology. The 2019 workshops will take place Friday, December 6, 2019, from 1:00 p.m. to 6:00 p.m. in Orlando, FL.

All registered ASH annual meeting attendees are welcome to attend these workshops. There is no additional fee to attend.

For questions about the 2019 Friday Scientific Workshop, please contact ASH Scientific Affairs Manager Alice Kuaban at akuaban@hematology.org.

Friday Scientific Workshop on Myeloid Development

Friday, December 6, 2019, 1:00 p.m. - 6:00 p.m.
Orange County Convention Center
Orlando, FL

Co-Chairs:

Patricia Ernst, PhD
University of Colorado, Anschutz Medical Campus
Aurora, CO
patricia.ernst@cuanschutz.edu

Ross Levine, MD
Memorial Sloan Kettering Cancer Center
New York, NY
leviner@mskcc.org

This workshop will examine the latest scientific findings in myeloid biology in a highly interactive environment that permits the exchange of ideas among investigators. It will focus on topics such as hematopoietic stem cell biology, leukemogenesis, cell signaling, transcription factors, epigenetic effects, and other topics related to myeloid biology. Each session leader will briefly summarize the current questions facing the field and then lead discussions on how best to answer those questions. New findings on novel techniques that provide insight into these questions will be an essential part of all discussions. The research presented at this workshop will also focus on the use of molecular biology and biochemistry tools, as well as animal models, to address the core topics. This workshop will not include any purely clinical, epidemiologic, or population-based approaches and will feature brief didactic sessions followed by a brief period for questions and answers.

Target Audience: This workshop is directed at laboratory-based investigators, and is meant to also attract young investigators, who will have an opportunity to interact directly with experts in the field. In addition, the broad-ranging content and highly interactive format of this workshop might also appeal to clinically oriented investigators.

Objectives:

  1. Discuss the latest scientific developments in hematopoietic stem cell biology, leukemogenesis, cell signaling, transcription factors, epigenetic effects, and other topics related to myeloid biology.
  2. Have interactive presentations by world-class scientists.
  3. Provide young investigators opportunities to interact with world-renowned experts in the field.

Sessions and Moderators:

Stem Cells
Eric Pietras, PhD
University of Colorado, Anschutz Medical Campus
Aurora, CO
eric.pietras@cuanschutz.edu

Signaling and Developmental Hematopoiesis
Claudia Lengerke, PhD
University of Basel
Basel, Switzerland
claudia.lengerke@unibas.ch

Myeloid Malignancies
Ben Ebert, MD, PhD
Dana-Farber Cancer Institute
Boston, MA
benjamin_ebert@dfci.harvard.edu

Transcription Factors
Ulrich Steidl, MD, PhD
Albert Einstein College of Medicine, Montefiore Medical Center
New York, NY
ulrich.steidl@einstein.yu.edu

New Investigators
Nancy Speck, PhD
University of Pennsylvania
Philadelphia, PA
nancyas@upenn.edu

All are welcome to attend this workshop. There is no additional fee, but ASH annual meeting registration is required.

A detailed program for this workshop will be available in October.

If you would like to request a speaking slot at this workshop, please contact the moderators directly.

back to top

Friday Scientific Workshop on Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure

Friday, December 6, 2019, 1:00 p.m. - 6:00 p.m.
Orange County Convention Center
Orlando, FL

Co-Chairs:

Lucy A. Godley, MD, PhD
The University of Chicago
Chicago, IL
lgodley@medicine.bsd.uchicago.edu

Marcin W. Wlodarski, MD, PhD
St. Jude Children’s Hospital
Memphis, TN
University of Freiburg
Freidburg, Germany
marcin.wlodarski@stjude.org

This workshop will review the latest advances in understanding the mechanisms leading to the phenotypes associated with inherited hematopoietic malignancies and bone marrow failure. Talks will concentrate on emerging data regarding recognized syndromes as well as novel susceptibility syndromes. It will feature an update on the work of the Clinical Genome Resource (ClinGen) initiative which aims to functionally annotate variants for RUNX1 and GATA2 (an effort that is jointly sponsored by ASH and ClinGen), as well as efforts of several international consortia that have formed to study these conditions. The workshop will also include an in-depth discussion about the newly identified MECOM syndrome. The ethical discussion this year will focus on when and how scientific advances in clonal hematopoiesis influence patient discussions and management regarding progression to malignancy.

Target Audience: Given the increasing number of recognized syndromes, and the existence of new initiatives, this workshop will appeal to a multidisciplinary audience from many countries.

Objectives:

  1. Discuss on-going research efforts and facilitate collaboration between experts in the field.
  2. Promote junior scientists.
  3. Discuss novel entities or new aspects of known germline susceptibility syndromes.
  4. Educate ASH members who are clinicians on testing standards and establish a network of specialist providers for consultations and transitioning of patients.
  5. Address an ethical dilemma regarding genetic testing in germline mutation carriers.

Sessions and Moderators:

Modeling Germline Predisposition Syndromes in Vitro and in Vivo
Paul Liu, MD, PhD
National Human Genome Research Institute
Bethesda, MD

Jun Yang, PhD
St. Jude Children’s Hospital
Memphis, TN

MECOM (RUSAT2) Syndrome: Clinical and Biological Aspects
Thierry Leblanc, MD
Hôpital Robert Debré
Paris, France

Panagiotis Baliakas, MD, PhD
Uppsala University
Uppsala, Sweden

International Collaborations to Advance Knowledge about Predisposition Syndromes
Anna Brown, PhD
University of South Australia
Adelaide, Australia

Akiko Shimamura, MD, PhD
Boston Children’s Hospital
Boston, MA

Discussion of Expert Gene Variant Curation
Michael Chicka, PhD
Prevention Genetics
Marshfield, WI

Chimene Kesserwan, MD
Yeshiva University
Bronx, NY

Ethical Discussion: How Do We Incorporate Molecular Profiling Results into Patient Recommendations During Surveillance for At-Risk Germline Mutation Carriers?
Kayla Hamilton, CGC
Dana-Farber Cancer Center
Boston, MA

Sara Lewis, CGC
St. Jude Children’s Hospital
Memphis, TN

Exciting New Research Findings
Outi Kilpivaara, PhD
University of Helsinki
Helsinki, Finland

Elvira Velloso, MD
University of Sao Paulo
Sao Paulo, Brazil

All are welcome to attend this workshop. There is no additional fee, but ASH annual meeting registration is required.

A detailed program for this workshop will be available in October.

If you would like to request a speaking slot at this workshop, please complete this form and submit it to the Co-chairs of the workshop directly using the email addresses noted above. The completed form should be submitted by October 11, 2019 and should denote in which session you would like to present as well as a brief description of your research (half page maximum).

back to top

Friday Scientific Workshop on Tumor Immune Interactions in Lymphoid Malignancies

Friday, December 6, 2019, 1:00 p.m. - 6:00 p.m.
Orange County Convention Center
Orlando, FL

Co-Chairs:

Stephen M. Ansell, MD, PhD
Mayo Clinic
Rochester, MN
ansell.stephen@mayo.edu

Ronald Levy, MD
Stanford University
Stanford, CA
levy@stanford.edu

The area of immunotherapy in lymphoid malignancies has exploded in recent years. Multiple new immune therapies are in development in lymphoproliferative diseases, and this exciting progress has been due to an increased understanding of the tumor microenvironment and tumor-immune interactions in these diseases. This proliferation of scientific knowledge has led to multiple potential new treatments, including new immune checkpoint blockade therapies, novel T-cell approaches, agents targeting monocytes, and macrophages, as well as new approaches inhibiting immune receptors and cytokine signaling. This workshop will focus on: (1) lymphoid malignancies; (2) the role of the immune system and tumor microenvironment; as well as (3) the current basic science to identify “what’s new” and predict “what’s next” in the world of immunotherapy. There will be no presentations on clinical/treatment strategies.

This workshop’s aim is to have scientists and translational researchers “hear it here first” when it comes to the next big thing in the management of lymphoid diseases. Attendees will benefit from interactive presentations by world-class scientists. The workshop will be somewhat speculative (though based on science), with a strong focus on future translation immune-related research.

Finally, this workshop will reinforce the appeal for scientists from around the world to attend the ASH and could serve as an introduction to the scientific content that will be presented during the meeting.

Target Audience: This workshop is directed at laboratory-based investigators, translational and clinical scientists interested in lymphoid biology and the tumor microenvironment.

Objectives:

  1. Highlight novel basic science and translational immune research in lymphoid malignancies that are likely to translate in the near future to clinically relevant therapies, biomarkers, or correlative science.
  2. Feature new methods of immune monitoring, as well as potential therapeutic targets that are likely to be important in lymphoid malignancies.

All are welcome to attend this workshop. There is no additional fee, but ASH annual meeting registration is required.

A detailed program for this workshop will be available in October.

back to top

Friday Scientific Workshop on the Interplay Between Coagulation and Malignancy

Friday, December 6, 2019, 1:00 p.m. - 6:00 p.m.
Orange County Convention Center
Orlando, FL

Co-Chairs:

Lisa Baumann Kreuziger, MD, MS
Blood Research Institute, Versiti
Milwaukee, WI
lkreuziger@versiti.org

Jeffrey Zwicker, MD
Beth Israel Deaconess Medical Center
Boston, MA
jzwicker@bidmc.harvard.edu

Coagulation pathways and the malignant state are reciprocally interwoven. Cancer has classically been associated with the development of venous thromboembolism. However, there is emerging evidence demonstrating that coagulation pathways also play a role in tumor progression. This workshop will serve as a forum to present and discuss basic and translational investigations in the field of cancer associated thrombosis with the goal of fostering research and collaboration.

Target Audience: This workshop is directed at basic scientists and researchers interested in the mechanisms of thrombosis in cancer patients and how thrombosis may influence the progression of cancer. The interactive format and potential for identification of collaborators may also be of interest to clinically oriented investigators. In an effort to facilitate mentoring opportunities, participation by junior and senior investigators is also encouraged.

Objectives:
  1. Provide a unique forum to discuss the latest scientific developments in cancer and thrombosis.
  2. Enhance current collaborations, develop new collaborations, and provide opportunities for interaction between junior and established investigators in cancer and thrombosis.
  3. Consider opportunities to refine and strengthen ASH's Agenda for Hematology Research on Venous Thromboembolic Disease by incorporating cancer-related knowledge gaps.

Sessions and Moderators:

Myeloproliferative Neoplasms and Thrombosis
Ann Mullally, MD
Dana-Farber Cancer Institute
Boston, MA

Joan Beckman, MD, PhD
University of Minnesota
Minneapolis, MN

Interplay Between the Coagulation System and Solid Tumor Progression Part 1
Lalitha Nayak, MD
Case Western Reserve University
Cleveland, OH

Christophe Dubois, PhD
Aix-Marseille Université
Marseille, France

Interplay Between the Coagulation System and Solid Tumor Progression Part 2
Agnes Lee, MD, MSc
University of British Columbia
Vancouver, BC, Canada

Wolfram Ruf, PhD
Johannes Gutenberg University Medical Center
Mainz, Germany

All are welcome to attend this workshop. There is no additional fee, but ASH annual meeting registration is required.

A detailed program for this workshop will be available in October.

back to top

Friday Scientific Workshop on Hematology and Aging: From Bleeding Disorders to Malignant Hematology

Friday, December 6, 2019, 1:00 p.m. - 6:00 p.m.
Orange County Convention Center
Orlando, FL

Co-Chairs:

Ashley Rosko, MD
The Ohio State University
Columbus, OH
ashley.rosko@osumc.edu

Rebecca L. Olin, MD, MS
University of California – San Francisco
San Francisco, CA
rebecca.olin@ucsf.edu

The number of older adults with hematologic disorders is increasing dramatically. Understanding evidence gaps and exploring novel advances in the aging biology is relevant to improving outcomes for older adults with hematologic disorders. This workshop will focus on understanding the implications of aging on the development, progression, and treatment of hematologic disorders. Its interactive format will feature brief didactic presentations from speakers on key topics followed by a few minutes of questions and answers.

Target Audience: This workshop is directed at laboratory-based investigators and clinician researchers with an interest in aging and hematology. However, the wide-ranging content, thematic focus, and interactive format may appeal to a broader audience, including students and trainees.

Objectives:

  1. Provide a forum within the ASH annual meeting for presentation of novel research related to the biology of aging and hematologic disorders.
  2. Highlight areas of active research including the integration of geroscience principles into hematology, with a focus on myeloid and lymphoid malignancies as well as bleeding and clotting disorders.
  3. Foster collaboration and networking so as to facilitate bidirectional discussions between investigators focused on pre-clinical, translation, and clinical models of aging.

Sessions and Moderators:

Keynote Address
Felipe Sierra, PhD
National Institute on Aging
Bethesda, MD

Myeloid Biology and Neoplasia
Heidi Klepin, MD, MS
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, NC

Multiple Myeloma and Aging
Tanya Wildes, MD, MSCI
Washington University School of Medicine in St. Louis
St. Louis, MO

Lymphoma and Chronic Lymphocytic Leukemia (CLL): Mechanisms of Efficacy and Toxicity
Reena Jayani, MD
Vanderbilt University
Nashville, TN

Bleeding and Clotting
Michelle Lavin, MB, BCh, PhD
Royal College of Surgeons in Ireland
Dublin, Ireland

Aging and Cancer Drug Approvals
Bindu Kanapuru, MD
U.S. Food and Drug Administration
Washington, DC

All are welcome to attend this workshop. There is no additional fee, but ASH annual meeting registration is required.

A detailed program for this workshop will be available in October.

If you would like to request a speaking slot in a future workshop, please contact the Co-chairs directly.

back to top

Friday Scientific Workshop on Novel Curative Options: Gene-Editing and Gene Therapy for Hemoglobinopathies with a Focus on Sickle Cell Disease

Friday, December 6, 2019, 1:00 p.m. - 6:00 p.m.
Orange County Convention Center
Orlando, FL

Co-Chairs:

Alexis A. Thompson, MD
Ann and Robert H. Lurie Children’s Hospital of Chicago
Chicago, IL
a-thompson@northwestern.edu

Punam Malik, MD
Cincinnati Children’s Hospital Medical Center
Cincinnati, OH
punam.malik@cchmc.org

In an effort to address limitations of genomic approaches to cures, this workshop will seek to discuss the latest basic and translational strategies for the development of curative therapies. Additive gene therapy using lentiviral vectors for manipulating hematopoietic stem cells (HSC) has resulted in high-level stable reconstitution in early clinical trials. Furthermore, with the discovery of CRISPR/Cas9 system, one can now also edit the genome and directly correct the mutation. Correcting the β-globin gene defect in a patient’s HSCs and restoring clinically active levels of hemoglobin de novo conceptually opens the possibility of a safer, universally available therapy with important ameliorative and even curative potential. This workshop will discuss strategies aimed at optimizing gene therapy approaches; address current challenges in gene editing of HSCs; as well as preclinical and regulatory barriers and/or concerns. Relevant endpoints and outcome measures of these new therapies and initiatives to accelerate cures will also be presented and discussed.

The format of this workshop is intended to be interactive and will bring together a diverse group of both scientific and clinical stakeholders in this rapidly evolving arena.

Target Audience: This workshop is directed at basic and translational scientists who are interested in gene therapy, gene-editing, and other genomic modifications, and their applications to blood disorders such as the hemoglobinopathies. The contents and the interactive format should also attract young investigators entering this field.

Objectives:

  1. Discuss the latest scientific approaches for gene editing and gene therapy for sickle cell disease.
  2. Provide an interactive forum that facilitates discussions about challenges and barriers to translation, including, preclinical development, regulatory challenges, and Investigational New Drug enabling requirements.
  3. Discuss endpoints for gene editing and gene therapy trials, and the supportive efforts by ASH and the National Institutes of Health at accelerating genetic curative therapies.

Moderators:

Donald Kohn, MD
University of California – Los Angeles
Los Angeles, CA

Daniel Bauer, MD, PhD
Dana-Farber Cancer Institute
Cambridge, MA

Matthew Porteus, MD, PhD
Stanford Medical School
Stanford, CA

Punam Malik, MD
Cincinnati Children’s Hospital Medical Center
Cincinnati, OH

Alexis A. Thompson, MD
Ann and Robert H. Lurie Children’s Hospital of Chicago
Chicago, IL

Mark Walters, MD
Children’s Hospital and Research Center - Oakland
Oakland, CA

All are welcome to attend this workshop. There is no additional fee, but ASH annual meeting registration is required.

A detailed program for this workshop will be available in October.

back to top

Friday Scientific Workshop on Innovation in Clinical Trials Design

Friday, December 6, 2019, 1:00 p.m. – 6:00 p.m.
Orange County Convention Center
Orlando, FL

Co-Chairs:

Alan E. Mast, MD, PhD
Blood Center of Wisconsin
Milwaukee, WI
alan.mast@bcw.edu

Grzegorz S. Nowakowski, MD
Mayo Clinic
Rochester, MN
nowakowski.grzegorz@mayo.edu

This workshop will address current and emerging concepts in the design of clinical trials, including challenges and solutions specific to malignant and non-malignant hematologic diseases. It will also provide a platform for open discussion of available methodology and resources for conducting clinical trials in hematology. The focus will be on novel statistical methodology, use of real-world data in drug development and clinical trial interpretation, solutions for study conduct in rare diseases, and incorporation of innovative endpoints in trials to accelerate drug development for hematologic diseases. Speakers will briefly summarize the current and emerging approaches, while session moderators will facilitate discussion with panelists. The discussions during each session will also be directed at the identification of potential collaborations between multiple stakeholders (i.e., clinicians, statisticians, regulatory authorities, and industry sponsors) involved in hematology clinical trials, and ways to foster such partnerships.

The format of this workshop will include a keynote address, and 3 didactic sessions each consisting of 3 brief talks with panel discussions followed by questions and answers.

Target Audience: This workshop is directed at translational researchers, clinical investigators, industry sponsors and statisticians involved in clinical trial design. The content might be particularly appealing to young investigators wishing to explore careers in clinical trial design and conduct. As such, this workshop will provide them with an opportunity to interact directly with experts in the field, sponsors, and regulators.

Objectives:

  1. Provide an overview of novel statistical approaches involved in the design of clinical trials for hematologic malignancies.
  2. Discuss ways to incorporate real-world data (RWD) in drug developing and how RWD can aid trial design.
  3. Discuss how novel endpoints can be incorporated in clinical trials and drug and cell therapy development.
  4. Provide young investigators opportunities to interact with world-renowned experts in the field.
  5. Provide an open forum for discussion of ways clinical trials in hematology can be improved, in order to facilitate drug approval and application of such new therapies into clinical practice.

Sessions:

Keynote Address: Utilization of Real-World Data in Drug Development for Hematologic Diseases

Session 1: Innovative Trial Design – Can We Do More Utilizing What’s Already There?

Session 2: Impact of Trial Design on Outcome

Session 3: Beyond Response Rate: Novel Endpoints in Clinical Trials

All are welcome to attend this workshop. There is no additional fee, but ASH annual meeting registration is required.

A detailed program for this workshop will be available in October.

back to top

Friday Scientific Workshop on Integrative Epidemiology: Translating Epidemiology and Basic Science to Maximize Clinical Impact

Friday, December 6, 2019, 1:00 p.m. - 6:00 p.m.
Orange County Convention Center
Orlando, FL

Co-Chairs:

Wendy Cozen, DO, MPH
University of Southern California
Los Angeles, CA
wcozen@usc.edu

James Foran, MD
Mayo Clinic Florida
Jacksonville, FL
foran.james@mayo.edu

Epidemiologic research is of increasing importance in the era of large-scale genomics and databases, where large numbers of patients must be accumulated to study subtle individual effects that translate into large populations. The workshop will address fundamental questions regarding the development, prevention and prognosis of hematologic diseases in different populations with an emphasis on translational potential. It will provide a forum for epidemiologists working on hematologic diseases to present timely research topics and allow for fundamental scientists to present work (i.e., big data, molecular studies and new technologies) that could be translated from the bench to the real-world population.

The workshop will be comprised of two consecutive sessions each with eight speakers giving focused, 15-minute, cutting-edge presentations on the clinical and molecular epidemiology of hematologic malignancies. The presentations will include audience/attendee interaction and discussion, followed by panel discussions.

Target Audience: This workshop is directed at epidemiologists focusing on hematologic neoplasms and benign hematologic disorders as well as basic and clinical scientists interested in real-world population applications of their findings. The workshop will also appeal strongly to trainees in clinical hematology-oncology who are interested in expanding their careers to include an epidemiologic focus.

Objectives:

  1. Provide a unique forum at the ASH annual meeting to discuss and present advances in the field of epidemiology of hematologic diseases, with a focus on malignancies.
  2. Extend novel observations generated from epidemiology studies to translational studies with direct clinical relevance and to provide an opportunity to integrate new molecular or bench findings into population studies.
  3. Develop a roadmap and future directions that advance the study of epidemiology, particularly including prevention strategies for lymphoid and myeloid malignancy and benign hematologic disorders.
  4. Establish a forum that enhances current collaborations, develops new collaborations, and provides opportunities for career development and research for trainees and junior investigators in the field of epidemiology of hematologic malignancy and benign hematologic disorders.

Sessions and Moderators:

Updates on Epidemiology and Translational Research Opportunities: Lymphoid Malignancies and Non-malignant Hematologic Disorders
James Cerhan, MD, PhD
Mayo Clinic
Rochester, MN

Wendy Cozen, DO, MPH
University of Southern California
Los Angeles, CA

Epidemiology of Myeloid Malignancy: Precursor States and Risk Factor Update
Lindsay Morton, PhD
National Cancer Institute
Bethesda, MD

James Foran, MD
Mayo Clinic Florida
Jacksonville, FL

All are welcome to attend this workshop. There is no additional fee, but ASH annual meeting registration is required.

A detailed program for this workshop will be available in October.

back to top

Friday Scientific Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma

Friday, December 6, 2019, 1:00 p.m. – 6:00 p.m.
Orange County Convention Center
Orlando, FL

Co-Chairs:

Philip McCarthy, MD
Roswell Park Comprehensive Cancer Center
Buffalo, NY
philip.mccarthy@roswellpark.org

Saad Usmani, MD
Levine Cancer Institute/Atrium Health
Charlotte, NC
saad.usmani@atriumhealth.org

This workshop will present and examine the latest scientific translational findings in immunology and molecular biology of plasma cell disorders (PCDs) with emphasis on multiple myeloma and related monoclonal plasma cell diseases. The workshop will focus on topics including: (1) plasma cell biology, the complex molecular landscape of myeloma; (2) immune profiling during the treatment of PCD including flow cytometric and CyTOF analyses; (3) the bone marrow and immune environment during the progression of PCDs; (4) the role of minimal residual disease testing for predicting outcome; (5) predicting response to new treatment technologies including Chimeric Antigen Receptor T-cell and Natural Killer (CAR-T cell and NK) cell therapies; (6) monoclonal derived therapies; (7) imaging techniques for determining response; and (8) functional disease assessment including strategies for estimating/predicting long term response and outcome. Sessions will consist of four to five 10-minute fundamental science and translational presentations. Each session will be chaired by a leader who will summarize the current state of the field and facilitate discussion with the audience and the speakers.

Target Audience: This workshop is directed toward basic science investigators in the field of PCD. It is designed to be interactive with an emphasis on understanding the biology of PCD so as to develop new translational strategies to bring to the clinic from the laboratory. Trainees and junior investigators are encouraged to attend this workshop so as to interact with experts in PCD.

Objectives:

  1. Discuss the latest scientific developments in PCDs with an emphasis on the immunology and molecular biology of PCDs.
  2. Encourage interaction of investigators from around the world.
  3. Encourage trainees and other investigators to participate in the discussion of presentations of experts in the field of PCDs.

Sessions and Moderators:

The Molecular and Immunobiology of PCD from Diagnosis to Therapy
Saad Usmani, MD
Levine Cancer Institute/Atrium Health
Charlotte, NC

Adaption of Next Generation Sequencing, Next Generation Flow Cytometry, CyTOF and New Approaches to Bone and Soft Tissue Imaging of PCD

Jens Hillengass, MD
Roswell Park Comprehensive Cancer Center
Buffalo, NY

Chimeric Antigen Receptor T-Cell Therapy for PCD with an Emphasis on Multiple Myeloma
Marcelo Pasquini, MD
Medical College of Wisconsin
Milwaukee, WI

Adapting Novel Techniques into Clinical Endpoints for PCD
Sarah Holstein, MD, PhD
University of Nebraska Medical Center
Omaha, Nebraska

All are welcome to attend this workshop. There is no additional fee, but ASH annual meeting registration is required.

A detailed program for this workshop will be available in October.

If you would like to request a speaker slot at this workshop, please contact the Co-chairs directly and cc Amy Foley at afoley@nmdp.org to see if a speaker slot is still available.

back to top